v3.26.1
Commitments and Contingencies (Details)
$ in Thousands, € in Millions
1 Months Ended 2 Months Ended 3 Months Ended
May 22, 2025
defendant
May 13, 2025
defendant
May 05, 2025
USD ($)
Mar. 26, 2025
defendant
Apr. 30, 2020
USD ($)
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
plaintiff
Mar. 31, 2025
USD ($)
Apr. 01, 2026
USD ($)
study
Mar. 31, 2026
EUR (€)
Long-term Purchase Commitment [Line Items]                    
Payment of contingent consideration             $ 0 $ 4,900    
Forecast                    
Long-term Purchase Commitment [Line Items]                    
Payment of contingent consideration           $ 10,000        
Merger Agreement | Sage Litigation                    
Long-term Purchase Commitment [Line Items]                    
Number of plaintiff | plaintiff             2      
Derivative Litigation | Sage Litigation                    
Long-term Purchase Commitment [Line Items]                    
Number of defendants | defendant 16 16   16            
USWM Acquisition                    
Long-term Purchase Commitment [Line Items]                    
Annual minimum purchase quantity requirement amount | €                   € 3.0
Navitor Pharmaceuticals, Inc.                    
Long-term Purchase Commitment [Line Items]                    
Collaborative arrangement, termination notice period         30 days          
Threshold for development costs payments         $ 50,000          
Collaborative arrangement, payment for one time fee         10,000          
Collaborative arrangement, upfront development costs         25,000          
Collaborative arrangement, acquisition-related cost, expense     $ 100,000              
Navitor Pharmaceuticals, Inc. | Subsequent Event                    
Long-term Purchase Commitment [Line Items]                    
Collaborative arrangement, number of studies | study                 1  
Collaborative arrangement, contingent consideration, maximum                 $ 350,000  
Navitor Pharmaceuticals, Inc. | Minimum                    
Long-term Purchase Commitment [Line Items]                    
Collaborative arrangement, expected development costs         410,000          
Navitor Pharmaceuticals, Inc. | Maximum                    
Long-term Purchase Commitment [Line Items]                    
Collaborative arrangement, expected development costs         475,000          
Navitor Pharmaceuticals, Inc. | Variable Interest Entity, Not Primary Beneficiary                    
Long-term Purchase Commitment [Line Items]                    
Investments         $ 15,000          
VIE, qualitative or quantitative information, ownership percentage         13.00%